General Information of Drug (ID: DM27J3D)

Drug Name
BLU-554 Drug Info
Synonyms
MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 1 [1]
Cross-matching ID
PubChem CID
91885617
CAS Number
CAS 1707289-21-1
TTD Drug ID
DM27J3D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS-FGFR4 DMNVZDT Obesity 5B81 Phase 2 [2]
FGF401 DMWEJ0C Hepatocellular carcinoma 2C12.02 Phase 1/2 [1]
H3B-6527 DMAYTRK Hepatocellular carcinoma 2C12.02 Phase 1 [1]
PD-0183812 DMWYP86 Retinoblastoma 2D02.2 Terminated [3]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
FGFR4 messenger RNA (FGFR4 mRNA) TT1KX2S FGFR4_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
3 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
4 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.